Fundraising Fox

Synendos

Basel, CH · Founded 2019 · 17 employees on LinkedIn · 10 known investors

Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders. The company's lead candidate, SYT-510, is in clinical development with the goal of restoring brain function in major psychiatric and neurological conditions.

BiotechDeep TechDigital HealthMental Health

Founders & leadership

Synendos was founded in 2019 by Prof. Jürg Gertsch, Dr. Andrea Chicca, and Dr. Simon Russell.

PJ
Prof. Jürg GertschFounder
DA
Dr. Andrea ChiccaCo-Founder & Chief Executive Officer
DS
Dr. Simon RussellCo-Founder & Chief Commercial Officer

Investors · 10

Kurma Partners✓ verifiedParis · $162K – $10.8M
Ysios Capital✓ verifiedBarcelona · $5.4M – $21.6M
Sunstone CapitalFrederiksberg

Also in the syndicate · 7

BERNINA BioInvestEssential InvestmentsHigh-Tech GründerfondsLichtsteiner FoundationSchroder AdveqSunstone Life Science VenturesleadZürcher Kantonalbank

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries ANov 2020

    Kurma Partners (lead), Sunstone Life Science Ventures (lead), BERNINA BioInvest, Essential Investments, High-Tech Gründerfonds, Lichtsteiner Foundation, Schroder Adveq, Zürcher Kantonalbank

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions - Pharmaceutical Technologypharmaceutical-technology.com · Jan 2024Synendos Therapeutics expands series A to $25 Million - BaseLaunchbaselaunch.ch · Apr 2021April 2021 // Investmentsynendos.com · Apr 2021November 2020synendos.com · Nov 2020Synendos Therapeutics Raises CHF 20 Million in Series A Financingprnewswire.com · Nov 2020

Frequently asked questions

What does Synendos do?
Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders. The company's lead candidate, SYT-510, is in clinical development with the goal of restoring brain function in major psychiatric and neurological conditions.
Who founded Synendos?
Synendos was founded by Prof. Jürg Gertsch, Dr. Andrea Chicca, Dr. Simon Russell in 2019.
Who are Synendos's investors?
Synendos's investors include Kurma Partners, Ysios Capital, Sunstone Capital.
Where is Synendos headquartered?
Synendos is headquartered in Basel, CH.